Financial Performance - The company's revenue for Q3 2024 was ¥92,126,731.98, representing a decrease of 32.60% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥6,165,534.97, down 80.41% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was -¥1,511,042.32, a decline of 104.89% compared to the previous year[2]. - Total operating revenue for Q3 2024 was CNY 333,993,687.09, a decrease of 38.5% compared to CNY 542,445,746.24 in the same period last year[13]. - Net profit for Q3 2024 was CNY 74,661,546.28, a decline of 48.3% compared to CNY 144,514,979.02 in Q3 2023[14]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 74,661,546.28, compared to CNY 144,514,979.02 in the same period last year, reflecting a decrease of approximately 48.3%[15]. - Basic and diluted earnings per share for Q3 2024 are both CNY 0.26, down from CNY 0.50 in the previous year, indicating a decline of 48%[15]. Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,437,069,095.83, a decrease of 4.30% from the end of the previous year[2]. - The total assets as of Q3 2024 amounted to CNY 2,437,069,095.83, a decrease from CNY 2,546,570,975.79 at the end of the previous quarter[12]. - Current liabilities totaled CNY 128,361,400.85, down 26.7% from CNY 175,141,355.55 in the previous quarter[12]. - Non-current liabilities amounted to CNY 13,278,812.72, a decrease from CNY 14,744,778.82 in the previous quarter[12]. - The company’s total equity attributable to shareholders decreased by 2.60% to ¥2,295,428,882.26 compared to the end of the previous year[2]. - The total equity attributable to shareholders of the parent company was CNY 2,295,428,882.26, down from CNY 2,356,684,841.42 in the previous quarter[12]. Cash Flow - The company's cash flow from operating activities for the first nine months of 2024 was ¥48,958,629.78, down 41.01% year-on-year[8]. - Cash inflows from operating activities for Q3 2024 amount to CNY 358,511,330.00, a decrease of 29.2% from CNY 506,313,229.59 in Q3 2023[16]. - Net cash flow from operating activities is CNY 48,958,629.78, down 41% from CNY 82,988,321.06 in the same quarter last year[17]. - Cash outflows from investment activities total CNY 1,173,472,855.41, significantly higher than CNY 119,570,288.07 in Q3 2023, indicating a substantial increase in investment expenditures[17]. - The net cash flow from investment activities is -CNY 1,085,211,025.10, compared to -CNY 119,192,777.18 in the previous year, showing a worsening of investment cash flow[17]. - Cash and cash equivalents at the end of Q3 2024 stand at CNY 520,745,020.94, a decrease from CNY 1,729,396,597.93 at the end of Q3 2023, reflecting a decline of approximately 69.9%[17]. - The company reported a cash outflow of CNY 138,240,000.00 for financing activities, up from CNY 96,000,000.00 in the previous year, indicating increased financing costs[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,979, with the top 10 shareholders holding 38.25% of the shares[9]. - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds 110,160,000 shares, accounting for 38.25% of the total[9]. - The top 10 shareholders include both natural persons and corporate entities, with significant stakes held by individuals related to the controlling shareholder[9]. - The company has not reported any changes in the number of preferred shareholders or any significant changes in restricted shares[9]. - The company has not engaged in any major financing or share lending activities during the reporting period[10]. Operational Metrics - The company experienced a 38.43% decline in total revenue for the first nine months of 2024, totaling ¥333,993,687.09, primarily due to reduced sales of ibuprofen[6]. - The basic earnings per share for Q3 2024 was ¥0.02, reflecting an 82.51% decrease compared to the same period last year[2]. - Research and development expenses for Q3 2024 were CNY 26,268,412.71, down 24.8% from CNY 34,932,093.15 in Q3 2023[13]. - The company reported a financial income of CNY 43,297,639.20, an increase from CNY 36,293,249.80 in the same period last year[14]. Changes in Financial Assets - The company reported a significant increase in trading financial assets, which rose by 747.61% to ¥1,096,806,208.33 due to the purchase of transferable large-denomination certificates of deposit[5]. - Trading financial assets increased significantly to ¥1,096,806,208.33 from ¥129,399,817.02[10]. - Accounts receivable rose to ¥65,278,637.33 from ¥52,444,817.42, indicating a growth of approximately 24.5%[10]. - Inventory decreased to ¥155,087,639.39 from ¥173,804,685.14, reflecting a decline of about 10.8%[10]. - Other receivables increased to ¥8,698,567.85 from ¥4,478,312.08, showing a growth of approximately 94.5%[10]. Audit and Compliance - The company has not undergone an audit for the Q3 2024 report[18].
亨迪药业(301211) - 2024 Q3 - 季度财报